EUVIMEDEUVIMED entdecken
EditorialKommentar

Flashback Foreword: Bevacizumab and Irinotecan in Recurrent Glioblastoma

Ingo K Mellinghoff iD

Journal of Clinical Oncology · 2023

DOI: 10.1200/jco.23.01865 ↗

Kurz gefasst

Editorial in der Zeitschrift Journal of Clinical Oncology, 2023. Verfasst von Ingo K Mellinghoff. Beteiligte Einrichtung: Former Associate Editor, Journal of Clinical Oncology, Alexandria, VA. Hauptthemen laut MEDLINE: Glioblastoma, Brain Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 1 Literaturangaben. Gefördert von: NCI NIH HHS, NINDS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaBrain NeoplasmsHumansBevacizumabIrinotecanNeoplasm Recurrence, LocalCamptothecinAntineoplastic Combined Chemotherapy ProtocolsAngiogenesis Inhibitors

Substanzen

BevacizumabIrinotecanCamptothecinAngiogenesis Inhibitors

Autor:innen und Institutionen

  • Former Associate Editor, Journal of Clinical Oncology, Alexandria, VA.
  • Department of Neurology, Memorial Sloan Kettering Cancer Center, New York City, NY.

ORCID-Profile: Ingo K Mellinghoff

Förderung

  • NCI NIH HHS
  • NINDS NIH HHS

Zitieren

APA

Mellinghoff, I. K. (2023). Flashback Foreword: Bevacizumab and Irinotecan in Recurrent Glioblastoma. Journal of Clinical Oncology. https://doi.org/10.1200/jco.23.01865

Vancouver

Mellinghoff IK. Flashback Foreword: Bevacizumab and Irinotecan in Recurrent Glioblastoma. Journal of Clinical Oncology. 2023. doi:10.1200/jco.23.01865

BibTeX
@article{Mellinghoff2023,
  author = {Mellinghoff, Ingo K},
  title = {Flashback Foreword: Bevacizumab and Irinotecan in Recurrent Glioblastoma},
  journal = {Journal of Clinical Oncology},
  year = {2023},
  doi = {10.1200/jco.23.01865}
}
Kostenlos starten →